TPC2 inhibition or loss suppresses virus uptake (Sakurai et al., 2015; Petersen et al., 2020), increases the risk to develop non-alcoholic steatohepatitis (NASH) and fatty liver disease (NAFLD); Grimm et al., 2014, p. 707]. The gene discussed is TPCN2; the disease is metabolic dysfunction-associated steatohepatitis.